Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~42 mi. (Augsburg, Germany, +94 more cities)

Gemeinschaftspraxis Dres. Heinrich / Bangerter

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~42 mi. (Augsburg, Germany, +228 more cities)

Haematologisch-Onkologische Praxis im Zentrum Augsburg /ID# 232052

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~43 mi. (Gauting, Germany, +172 more cities)

Asklepios Fachkliniken München-Gauting

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~43 mi. (Gauting, Germany, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~43 mi. (Gauting, Germany, +184 more cities)

Asklepios Fachkliniken München-Gauting

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~43 mi. (Gauting, Germany, +87 more cities)

Asklepios Fachkliniken Munchen-Gauting

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

~43 mi. (Gauting, Germany, +57 more cities)

GSK Investigational Site

Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition

cobolimab, +7 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~57 mi. (Munich, Germany, +130 more cities)

Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

~57 mi. (Munich, Germany, +3 more cities)

Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum

ER Positive, +2 more biomarkers

Breast Carcinoma

hormone therapy, +1 more drug

hormone therapy, +1 more type

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

~57 mi. (Munich, Germany, +37 more cities)

Klinikum Rechts der Isar der Technischen Universitat Munchen

ER Negative, +2 more biomarkers

Breast Carcinoma

ladiratuzumab vedotin, +1 more drug

chemotherapy, +2 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~62 mi. (Ulm, Germany, +150 more cities)

Universitaetsklinikum Ulm ( Site 0402)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

~62 mi. (Ulm, Germany, +127 more cities)

Universitaetsklinikum Ulm ( Site 2102)

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type